Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Mustafa Diken et al.|Cancer Research|2019Cited by 3
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Katrin Frenzel et al.|Clinical Trials|2019Cited by 2